Medtronic to showcase MiniMed™ 780G system data across diverse patient populations at the European Association for the Study of Diabetes (EASD) 61st Annual Meeting

Medtronic plc, a global leader in medical technology, announced it will present new data on its MiniMed™ 780G system at the upcoming European Association for the Study of Diabetes (EASD) 61st Annual Meeting in Vienna on September 15-19. The new clinical evidence will include areas where the company recently announced expanded indications, such as for use in type 2 diabetes in the U.S. and Europe, and young children and pregnancy* in Europe. Medtronic will also present real-world evidence on how the actionable insights of its Smart MDI system is benefiting people who manage their diabetes with multiple daily injections.

Ensuring broader patient populations have access to advanced diabetes technology is vital, as it allows more individuals to achieve better health outcomesⁱ and experience greater confidence and freedom when managing their condition. Access to technology reduces disparities in care^ii,iii,iv and supports a more inclusive approach to managing diabetes across all ages, sexes, ethnicities and socioeconomic backgrounds. The MiniMed™ 780G system is indicated for use* by individuals with insulin-requiring diabetes, including both type 1 and type 2.

SCIENTIFIC DATA

The following poster and oral scientific data presentations represent the work of Medtronic employees and independent investigators using Medtronic devices in their research.

• Achieved and sustained glycemic outcomes with reduction in burden: Three-year real-world follow-up of the MiniMed™ 780G system; oral presentation by Dr. Jennifer McVean, Medical Affairs Director, Medtronic Diabetes, on Tuesday, September 16, 3:00-3:15pm CET (8:00-8:15am CT) - London Hall
  
• Sustainable effect of an AID system in 2-6-year-olds: results from the LENNY trial extension phase; oral presentation by Assoc. Prof. Klemen Dovč, University Medical Center Ljubljana, Slovenia, on Tuesday, September 16, 2:45-3:00pm CET (7:45-8:00am CT) - London Hall
  
• MiniMed™ 780G system provides equal performance in female users compared to males in all age groups from pre-puberty to menopause; Short oral presentation by Dr. Sarah Siegelaar, Amsterdam University Medical Center, the Netherlands, on Wednesday, September 17, 11:45am CET (4:45am CT) - Station 14
  
• Good glycemic control is maintained for at least 12 months in MiniMed™ 780G system users with self-reported type 2 diabetes: a real-world analysis; short oral presentation by Prof. Sergio Di Molfetta, University of Bari Aldo Moro, Bari, Italy, on Thursday September 18, 2:00pm CET (7:00am CT) - Station 13
  
• Real-world results from the first 1'852 European InPen™ Smart MDI system users: association between user behaviour and outcomes; short oral presentation by Dr. Andrea Laurenzi, San Raffaele Hospital, Milan, Italy, on Thursday September 18, 2:00pm CET (7:00am CT) - Station 14

MEDTRONIC SPONSORED EVENTS

Medtronic Symposium: Expanding horizons of the MiniMed™ 780G system for all people living with diabetes. Monday, September 15, 4:00-5:00pm CET (9:00-10:00am CT), Beijing Hall, chaired by Dr. Gerlies Trieber, Consultant Endocrinology and Diabetology at Medical University of Graz, Austria, and Prof. Ohad Cohen, MD, Senior Global Medical Affairs Director, Medtronic Diabetes.

MEDTRONIC PRESENTATIONS

• "Unlocking potential: the MiniMed™ 780G system in type 2 diabetes" chaired by Prof. Ohad Cohen, MD, Senior Global Medical Affairs Director, Medtronic Diabetes, with speaker Prof. Kirsten Nørgaard, Specialist in endocrinology and internal medicine at Steno Diabetes Center, Copenhagen, Denmark on Wednesday, September 17, 4:00-4:30pm CET (9:00-9:30am CT), Arena (Hall A)
  
• "Redefining MDI therapy: the Smart MDI system", chaired by Prof. Ohad Cohen, MD, Senior Global Medical Affairs Director, Medtronic Diabetes with speakers Prof. Goran Petrovski, Medical Affairs Director, Medtronic Diabetes, and Prof. Laurent Crenier, Head of Endocrinology Department, University Hospital Brussels, Belgium on Thursday, September 18, 3:00-3:30 CET (8:00-8:30-am CT), Spotlight Stage, Exhibition Hall (Hall B).

Medtronic Exhibit Booth C2.01, Exhibition Hall (Hall B), featuring interactive components focused on diabetes technology, clinical outcomes and support offerings for healthcare professionals and people with diabetes. In-Booth Presentations will include:

• "Expanding horizons: MiniMed™ 780G system for children aged 2+ years"; in-booth presentation by Prof. Goran Petrovski, Medical Affairs Director, Medtronic Diabetes on Tuesday, September 16, 10:00-10:15am CET (3:00-3:15am CT).
  
• "Smart MDI system essentials: What it does and why it works"; in-booth presentation by Prof. Goran Petrovski, Medical Affairs Director, Medtronic Diabetes on Tuesday, September 16, 12:45-1:00pm CET (5:45-6:00am CT).
  
• "Advocating for Access to Automated Insulin Delivery Therapy"; in-booth presentation by Dr. Banshi Saboo, Chief Diabetologist, DiaCare, Ahmedabad, India on Tuesday, September 16, 2:45-3:00pm CET (7:45-8:00am CT).
  
• "A new world of real evidence insight: Discover Medtronic Galaxy service"; in-booth presentation by Prof. Tali Cukierman-Yaffe, Head of Endocrinology & Diabetes, Sheba Medical Center, Israel on Wednesday, September 17, 11:45am-12:00pm CET (4:45-5:00am CT).
  
• "Expanding horizons: MiniMed™ 780G system for pregnant women with type 1 diabetes"; Dr. Rosa Corcoy, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain on Wednesday, September 17, 12:45am-1:00pm CET (5:45-6:00am CT).
  
• "Smart MDI system essentials: What it does and why It works"; Shannon Edd, Sr Medical Affairs & Education Specialist, Medtronic Diabetes on Wednesday, September 17, 2:30-2:45pm CET (7:30-7:45am CT).

In Europe the MiniMed™ 780G system is indicated for use by individuals aged 2 years and older with insulin-requiring diabetes, whose total daily dose of insulin is 6 units per day or more. It can be used during pregnancy. In the U.S., the MiniMed™ 780G system is indicated for use by individuals with type 1 diabetes aged 7 years and older, and for insulin-requiring type 2 diabetes aged 18 years and older with clinical trials underway to examine the use of the MiniMed ™780G system in 2-6-year-olds. The MiniMed™ 780G system has not been approved for use in pregnancy by the FDA.

About the Diabetes Business at Medtronic
Medtronic Diabetes is on a mission to make diabetes more predictable, so everyone can embrace life to the fullest with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission - to alleviate pain, restore health, and extend life - unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Andrew Crawford
Global Communications
+41-79-378-1932

Ryan Weispfenning
Investor Relations
+1-763-505-4626

ⁱ Choudhary, Pratik et al. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study. The Lancet Diabetes & Endocrinology, Volume 10, Issue 10, 720 - 731
ⁱⁱ Zhou, Y., Patel, M., Hernandez, L., Kim, S., & Thomas, D. (2025). Trends and disparities in diabetes technology use among U.S. adults with type 1 diabetes: A national cohort study. JAMA Network Open, 8(3), e251234. https://doi.org/10.1001/jamanetworkopen.2025.1234
ⁱⁱⁱ Addala, A., Amedari, M.I., Figg, L.E. et al. Disparities in access to and use of diabetes technologies and therapeutics: a narrative review. Diabetologia (2025). https://doi.org/10.1007/s00125-025-06494-4
^iv Saboo et al. DTT: A Call-to-Action to Eliminate Barriers to Accessing Automated Insulin Delivery Systems for People with Type 1 Diabetes